JP2021501185A - 抗生物質耐性を処置するための組成物及び方法 - Google Patents

抗生物質耐性を処置するための組成物及び方法 Download PDF

Info

Publication number
JP2021501185A
JP2021501185A JP2020524273A JP2020524273A JP2021501185A JP 2021501185 A JP2021501185 A JP 2021501185A JP 2020524273 A JP2020524273 A JP 2020524273A JP 2020524273 A JP2020524273 A JP 2020524273A JP 2021501185 A JP2021501185 A JP 2021501185A
Authority
JP
Japan
Prior art keywords
composition
species
antibiotic resistance
abundance
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020524273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501185A5 (enExample
Inventor
クリストファー， バートン フォード，
クリストファー， バートン フォード，
ジェシカ ブライアント，
ジェシカ ブライアント，
エドワード， ジェイ． オブライエン，
エドワード， ジェイ． オブライエン，
Original Assignee
セレス セラピューティクス インコーポレイテッド
セレス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレス セラピューティクス インコーポレイテッド, セレス セラピューティクス インコーポレイテッド filed Critical セレス セラピューティクス インコーポレイテッド
Publication of JP2021501185A publication Critical patent/JP2021501185A/ja
Publication of JP2021501185A5 publication Critical patent/JP2021501185A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020524273A 2017-10-30 2018-10-30 抗生物質耐性を処置するための組成物及び方法 Pending JP2021501185A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762578698P 2017-10-30 2017-10-30
US62/578,698 2017-10-30
US201862741346P 2018-10-04 2018-10-04
US62/741,346 2018-10-04
PCT/US2018/058279 WO2019089643A1 (en) 2017-10-30 2018-10-30 Compositions and methods for treating antibiotic resistance

Publications (2)

Publication Number Publication Date
JP2021501185A true JP2021501185A (ja) 2021-01-14
JP2021501185A5 JP2021501185A5 (enExample) 2021-12-09

Family

ID=64607291

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020524273A Pending JP2021501185A (ja) 2017-10-30 2018-10-30 抗生物質耐性を処置するための組成物及び方法

Country Status (11)

Country Link
US (2) US12214002B2 (enExample)
EP (1) EP3703720A1 (enExample)
JP (1) JP2021501185A (enExample)
KR (1) KR20200079292A (enExample)
CN (1) CN111432826A (enExample)
AU (1) AU2018360561A1 (enExample)
BR (1) BR112020008552A2 (enExample)
CA (1) CA3080586A1 (enExample)
MX (1) MX2020004495A (enExample)
RU (1) RU2020117775A (enExample)
WO (1) WO2019089643A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014145958A2 (en) 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11090342B2 (en) 2016-04-11 2021-08-17 President And Fellows Of Harvard College Probiotic formulations for improving athletic performance
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
CA3080586A1 (en) * 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
WO2019191694A1 (en) * 2018-03-29 2019-10-03 Seres Therapeutics, Inc. Compositions and methods for treating inflammatory bowel diseases
US20210196766A1 (en) * 2018-05-24 2021-07-01 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
CN113164526A (zh) * 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
TW202116333A (zh) * 2019-07-05 2021-05-01 英商4D製藥研究有限公司 包含細菌品系之組成物
GB201911728D0 (en) * 2019-08-15 2019-10-02 Genome Res Ltd Bacterial composistions for the treatment of disease
AU2020394447A1 (en) * 2019-11-25 2022-07-14 Fitbiomics Inc. Compositions for improving athletic performance and methods of use thereof
CN111157722B (zh) * 2019-11-25 2022-10-11 广州惠善医疗技术有限公司 生物标志物的用途
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
KR20230035039A (ko) * 2020-06-11 2023-03-10 에벨로 바이오사이언시즈, 인크. 해리플린티아 아세티스포라를 사용하여 질환 및 장애를 치료하기 위한 조성물 및 방법
CN116529355A (zh) * 2020-08-14 2023-08-01 Ko生物技术有限公司 普氏栖粪杆菌菌株及其用途
CN116473222B (zh) * 2022-01-17 2025-10-17 中国科学院上海营养与健康研究所 调控脂质吸收的方法、组合物及其应用
CN114807348B (zh) * 2022-04-21 2024-05-07 济南大学 长链非编码rna lra-1及其干扰rna在治疗动脉粥样硬化中的应用
CN116042432B (zh) * 2022-07-14 2024-07-23 沈阳医学院 一种具有广谱抑菌性的新菌种及其抑菌物质的提纯
KR102874308B1 (ko) * 2024-09-09 2025-10-22 (주)에이스바이옴 신규한 리모실락토바실러스 퍼멘텀 abf21069 균주와 이를 포함하는 비알코올성 지방간 질환의 예방, 개선 및 항염활성 조성물

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009864A (en) 1958-09-18 1961-11-21 Union Carbide Corp Process control
US3228838A (en) 1959-04-23 1966-01-11 Union Carbide Corp Preservation of biological substances
US3009861A (en) 1961-01-13 1961-11-21 Alderton Gordon Isolation of bacterial spores
US3608030A (en) 1969-05-21 1971-09-21 Howard Tint Method of preparing a tablet dosage-form for the immunization of the intestinal tract with live virus preparations
US4077227A (en) 1976-11-12 1978-03-07 Regents Of The University Of Minnesota Method of freezing liquid material in which agglomeration is inhibited
US4205132A (en) 1978-07-17 1980-05-27 Microlife Technics, Inc. Lyophilization of bacteria
FI59925C (fi) 1980-01-11 1981-11-10 Esko Viljo Nurmi Foerfarande foer framstaellning av ett bakteriepreparat anvaendbart foer foerhindrande av salmonellainfektion hos fjaederfae
US4780987A (en) 1983-10-25 1988-11-01 Plant Genetics, Inc. Method for the preparation of hydrated, pregerminated seeds in gel capsules
US4655047A (en) 1985-03-25 1987-04-07 I.Q.F. Inc. Process for freezing or chilling
US4839281A (en) 1985-04-17 1989-06-13 New England Medical Center Hospitals, Inc. Lactobacillus strains and methods of selection
EP0439453B1 (en) 1987-10-12 1994-01-19 Exomed Australia Pty. Ltd. (ACN 051 976 446) Improved method for treatment of gastrointestinal disorders
US5045446A (en) 1988-08-26 1991-09-03 Cryopharm Corporation Lyophilization of cells
WO1990001335A1 (en) 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
GB2233343B (en) 1989-06-30 1993-07-07 Farmos Oy A bacterial preparation for use in poultry
JP2961182B2 (ja) 1990-03-09 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
JP2961184B2 (ja) 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
US5436002A (en) 1991-01-29 1995-07-25 Mycogen Corporation Bacillus thuringiensisisolate PS201T6 toxin
RU2035186C1 (ru) 1992-07-09 1995-05-20 Семен Рафаилович Резник Профилактический биопрепарат споролакт
CA2146747C (en) 1992-10-09 2006-12-19 Brian A. Naughton Liver reserve cells
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5851545A (en) 1995-08-25 1998-12-22 Sandoz Ltd. Insecticidal matrix and process for preparation thereof
DE69635496T2 (de) 1995-09-15 2006-07-27 Gerding, Dale N., Chicago Verfahren und zusammensetzung zur vorbeugung und behandlung von mit clostridium difficile assoziierten erkrankungen
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
AUPO430496A0 (en) 1996-12-19 1997-01-23 Arnott's Biscuits Limited Prebiotics and probiotics
US5965128A (en) 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli
US5951977A (en) 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
MXPA02000504A (es) 1999-07-12 2004-05-21 Clewer Ltd Oy Metodo de purificar agua, bacterias adecuadas para el metodo y uso de las mismas.
US6589771B1 (en) 1999-10-28 2003-07-08 Immunom Technologies, Inc. Methods for arousing dormant bacteria
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
US6613549B2 (en) 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
AU2002221004B2 (en) 2000-11-30 2007-01-25 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
US20020013270A1 (en) 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
KR100437497B1 (ko) 2001-03-07 2004-06-25 주식회사 프로바이오닉 로타바이러스 및 유해 미생물 억제 활성을 가지는 신규내산성 락토바실러스 루테리 프로바이오-16 및 이를함유하는 생균활성제
MXPA03009877A (es) 2001-05-04 2005-07-15 Univ Florida Clonacion y secuenciamiento de genes de piruvato decarboxilasa (pdc) a partir de bacterias y usos de los mismos.
ITMI20011632A1 (it) 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
GB0130789D0 (en) 2001-12-21 2002-02-06 King S College London Application of spores
US8383342B2 (en) 2002-04-24 2013-02-26 The University Of North Carolina At Greensboro Compositions, products, methods and systems to monitor water and other ecosystems
GB0212975D0 (en) 2002-06-06 2002-07-17 Mars Uk Ltd Mammalian animal composition
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
CA2559596A1 (en) 2003-03-13 2004-11-25 Universite De Moncton (Bureau De Soutien A L'innovation) Antioxidant producing bacterium and uses thereof
EP1631312B1 (en) 2003-04-23 2008-09-10 Medarex, Inc. Compositions and methods for the therapy of inflammatory bowel disease
US20060046246A1 (en) 2003-04-24 2006-03-02 Qiandong Zeng Genus, group, species and/or strain specific 16S rDNA sequences
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
US20050271643A1 (en) 2003-08-14 2005-12-08 Iryna Sorokulova Bacterial strains, compositions including same and probiotic use thereof
MXPA06001821A (es) 2003-08-18 2006-05-31 Bio Balance Corp Una composicion probiotica, liquida, estable, preparacion y aplicaciones de la misma.
US20050048515A1 (en) 2003-08-29 2005-03-03 Garner Bryan E. Methods for detecting and quantifying specific probiotic microorganisms in animal feed
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
WO2005074706A1 (en) 2004-02-03 2005-08-18 Universite De Montreal Use of live bacteria for growth promotion in animals
US7632520B2 (en) 2004-02-16 2009-12-15 Sanjeev Khandelwal Synergistic antibacterial formulation and to a method of making the same
US7854927B2 (en) 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
CA2586299C (en) 2004-11-01 2014-10-28 James W. Stave Method for detecting or enriching a target microorganism upon lysis of non-target bacteria with bacteriophage
EP2280085A3 (en) 2004-11-01 2011-02-23 George Mason University Compositions and methods for diagnosing colon disorders
US20060188523A1 (en) 2005-01-10 2006-08-24 Zhiheng Pei Methods for diagnosing and treating chronic tonsillitis
US7627437B2 (en) 2005-01-14 2009-12-01 Idaho Research Foundation Categorization of microbial communities
EP1869200B1 (en) 2005-03-25 2008-09-03 Universiteit Gent Enzymatic demethylation of flavonoids
US7993667B2 (en) 2005-03-25 2011-08-09 Kimberly-Clark Worldwide, Inc. Methods of manufacturing a medicated tampon assembly
BRPI0611492B1 (pt) 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5363811B2 (ja) 2005-09-28 2013-12-11 ノルディスク リバランス アクティーゼルスカブ 治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
WO2007136553A2 (en) 2006-05-18 2007-11-29 Biobalance Llc Bacterial strains, compositions including same and probiotic use thereof
US20090324638A1 (en) 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
JP5019563B2 (ja) 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
CN101472639A (zh) 2006-06-20 2009-07-01 皇家飞利浦电子股份有限公司 用于治疗胃肠疾病的电子胶囊
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
EE05459B1 (et) 2006-12-08 2011-08-15 Tartu �likool Sporogeense Bacillus smithii tvi TBMI12 MSCL P737 ja selle endospooride kasutamine probiootikumina, toidulisandina ning probiootiline kompositsioon
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
DE102006062250A1 (de) 2006-12-22 2008-06-26 Roland Saur-Brosch Verwendung einer Zusammensetzung aus Mineralstoffen und/oder Vitaminen und gegebenenfalls acetogenen und/oder butyrogenen Bakterien zur oralen oder rektalen Verabreichung für die Behandlung und Vorbeugung von abdominalen Beschwerden
WO2008083157A2 (en) 2006-12-29 2008-07-10 Washington University In St. Louis Altering pgc-1alapha, ampk, fiaf, or the gastrointestinal microbiota as a means to modulate body fat and/or weight loss in a subject
CA2699550C (en) 2007-09-12 2020-08-18 Targanta Therapeutics Corp. Method of inhibiting clostridium difficile by administration of oritavancin
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US8236508B2 (en) 2008-01-29 2012-08-07 Drexel University Detecting and measuring live pathogens utilizing a mass detection device
US8021654B2 (en) 2008-03-14 2011-09-20 Danisco A/S Methods of treating pigs with Bacillus strains
CA2720292A1 (en) 2008-04-01 2009-10-08 Metametrix Clinical Laboratory Process and method for monitoring gastrointestinal microbiota
CN101264107A (zh) 2008-05-09 2008-09-17 东北制药集团公司沈阳第一制药厂 地衣芽孢杆菌药物组合物及其制剂
CN102940652B (zh) 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
JP2011528117A (ja) 2008-07-15 2011-11-10 メタノミクス ヘルス ゲーエムベーハー 胃バイパス及びそれに関連する状態を診断する手段及び方法
JPWO2010024251A1 (ja) 2008-08-26 2012-01-26 オリンパス株式会社 糞便試料の調製方法、糞便試料調製用溶液、及び採便用キット
WO2010030997A1 (en) 2008-09-12 2010-03-18 The Washington University Regulating intestinal microbiota dependent signaling as a means to modulate body fat and/or weight loss
WO2010036876A2 (en) 2008-09-25 2010-04-01 New York University Compositions and methods for characterizing and restoring gastrointestinal, skin, and nasal microbiota
AU2009320350B2 (en) 2008-11-03 2015-09-24 Tufts University Methods and compositions for inhibiting Clostridium difficile spore germination and outgrowth
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
IT1392672B1 (it) 2009-01-12 2012-03-16 Wyeth Consumer Healthcare S P A Composizioni comprendenti componenti probiotici e prebiotici e sali minerali, con lactoferrina
IT1393931B1 (it) 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composizione di spore di batteri non patogeni
EP2421984A1 (en) 2009-04-20 2012-02-29 Qteros, Inc. Compositions and methods for fermentation of biomass
EP2432484A1 (en) 2009-04-30 2012-03-28 Compagnie Gervais Danone Use of collinsella aerofaciens for reducing bloating
KR20120015335A (ko) 2009-05-01 2012-02-21 마이크로파마 리미티드 퇴행성 질환의 예방 및 치료를 위한 박테리아 조성물
JP2010280640A (ja) 2009-06-08 2010-12-16 Kirin Holdings Co Ltd 穀類植物種子由来の不溶性食物繊維を含有する大腸癌予防用物質
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
WO2011046614A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2010151842A2 (en) 2009-06-26 2010-12-29 The Regents Of The University Of California Methods and systems for phylogenetic analysis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
ES2518490T3 (es) 2009-08-18 2014-11-05 Nestec S.A. Una composición nutritiva, la cual comprende cepas de Lactococcus y que reduce los síntomas de alergia, especialmente, en lactantes y en niños
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
WO2011022660A1 (en) 2009-08-21 2011-02-24 Puretech Ventures, Llc Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
GB0916335D0 (en) 2009-09-17 2009-10-28 Martin W J Medicaments
PL2480255T3 (pl) 2009-09-23 2018-07-31 Thomas Julius Borody Terapia przewlekłych zakażeń jelitowych
WO2011043654A1 (en) 2009-10-05 2011-04-14 Aak Patent B.V. Methods for diagnosing irritable bowel syndrome
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
US20120276149A1 (en) 2009-10-15 2012-11-01 Dan Littman Methods for modulating bacterial infection
PH12012500687A1 (en) 2009-11-12 2012-10-29 Nestec Sa Nutritional composition for promoting gut microbiota balance and health
CA2785658C (en) 2009-12-31 2017-10-24 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
US9492487B2 (en) 2010-02-01 2016-11-15 Matthew Ryan Garner Microbial product containing multiple microorganisms
FI4032586T3 (fi) 2010-02-01 2025-11-25 Ferring Microbiome Inc Bakteeriterapia clostridium difficile -koliittiin
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
EP2542690A2 (en) 2010-03-01 2013-01-09 Institut National de la Recherche Agronomique Method of diagnostic of inflammatory bowel diseases
AU2011223002B2 (en) 2010-03-01 2015-07-02 Institut National De La Recherche Agronomique Method of diagnostic of obesity
IT1398553B1 (it) 2010-03-08 2013-03-01 Probiotical Spa Composizione comprendente batteri probiotici per il trattamento di patologie associate con le alterazioni del sistema immunitario.
WO2011113801A1 (en) 2010-03-16 2011-09-22 Universiteit Gent Use of clostridium perfringens strain 23 to protect against necrotic enteritis
US8951512B2 (en) 2010-05-04 2015-02-10 New York University Methods for treating bone disorders by characterizing and restoring mammalian bacterial microbiota
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
WO2012009712A2 (en) 2010-07-16 2012-01-19 The Board Of Trustees Of The University Of Arkansas Methods and compositions including spore-forming bacteria for increasing the health of animals
FI20105825A7 (fi) 2010-07-26 2012-01-27 Suomen Punainen Risti Veripalvelu Veriryhmästatuksen käyttö III
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
BR112013002667B1 (pt) 2010-08-04 2020-02-04 Thomas Julius Borody composições para transplante da flora intestinal e métodos para fazê-las e usá-las e dispositivos para administrá-las
US9386793B2 (en) 2010-08-20 2016-07-12 New York University Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
US20130224164A1 (en) 2010-09-10 2013-08-29 Viropharma Incorporated Environmental Clostridial Bacteriotherapy and Related Formulations and Methods of Manufacture and Use
US20130259899A1 (en) 2010-10-04 2013-10-03 Allen-Vercoe, Emma Molecular And Cellular Biology University Of Guelph Detection of fusobacterium in a gastrointestinal sample to diagnose gastrointestinal cancer
US8802099B2 (en) 2010-11-10 2014-08-12 National Jewish Health Methods to treat allergic conditions
US20120064592A1 (en) 2011-01-26 2012-03-15 Qteros, Inc. Biocatalysts synthesizing deregulated cellulases
US8927252B2 (en) 2011-02-09 2015-01-06 Lavivo Ab Synbiotic compositions for restoration and reconstitution of gut microbiota
US8511540B2 (en) 2011-02-18 2013-08-20 Echostar Technologies L.L.C. Matrix code for use in verification of data card swap
AR085409A1 (es) 2011-02-25 2013-10-02 Tricorder Diagnostics Llc Firmas microbianas como indicadores de exposicon a radiacion
EP3610881A1 (en) 2011-03-09 2020-02-19 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
WO2012122522A2 (en) 2011-03-09 2012-09-13 Washington University Cultured collection of gut microbial community
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
US20120276056A1 (en) 2011-04-26 2012-11-01 Wieslaw Janusz Bochenek Method for Use of Biologic Agents Including Live or Dormant Forms of Bacteria and other organisms in Treating Infections, Inflammation and Other Diseases of Distal Small Intestine and Large Intestine
US20120278201A1 (en) 2011-04-26 2012-11-01 Dwolla Corp. Location transaction processing system
WO2012159023A2 (en) 2011-05-19 2012-11-22 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
US9579353B2 (en) 2011-06-10 2017-02-28 Prothera, Inc. Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
WO2013008102A2 (en) 2011-07-14 2013-01-17 R.E.D. Laboratories N.V../ S.A. Methods and compositions for evaluating and/or treating chronic immune diseases
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
CA2843388A1 (en) 2011-07-27 2013-01-31 Max International, Llc Compositions comprising sugar-cysteine products
WO2013019896A1 (en) 2011-08-01 2013-02-07 Symbiotix Biotherapies, Inc. Platform for identifying and/or characterizing immunomodulatory agents
JP6116568B2 (ja) 2011-08-30 2017-04-19 アカデミッシュ メディッシュ セントラム インスリン抵抗性を予防および／または処置する方法
CA2848762C (en) 2011-09-14 2021-07-27 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system
WO2013066369A2 (en) 2011-10-03 2013-05-10 The Regents Of The University Of Michigan Methods for detecting graft-versus-host disease
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
AU2012322979B2 (en) 2011-10-11 2017-02-02 Achim Biotherapeutics Ab Composition comprising anaerobically cultivated human intestinal microbiota
EP3569690B1 (en) 2011-12-01 2024-08-28 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
GB201201766D0 (en) 2012-02-01 2012-03-14 Imp Innovations Ltd Method
WO2013121573A1 (ja) 2012-02-17 2013-08-22 住友商事株式会社 ソフトバイオマスの分解方法
WO2013166031A1 (en) 2012-04-30 2013-11-07 The Washington University Method of isolating and characterizing microorganisms that are targets of host immune responses
EP3686284A1 (en) 2012-05-18 2020-07-29 Genome Research Limited Methods and groups
US9719144B2 (en) 2012-05-25 2017-08-01 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
AU2013266069B2 (en) 2012-05-25 2018-03-15 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
EP2684469A1 (en) 2012-07-13 2014-01-15 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Methods for strengthening and assessment of the natural defence of the colon against C. difficile overgrowth
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CN104955466A (zh) 2012-11-23 2015-09-30 赛里斯治疗公司 协同细菌组合物和其制造方法和用途
WO2014088982A1 (en) 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
KR102222273B1 (ko) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
WO2014121304A1 (en) 2013-02-04 2014-08-07 Seres Health, Inc. Compositions and methods
HK1220495A1 (zh) 2013-03-14 2017-05-05 Seres Therapeutics, Inc. 从材料和组合物中检测和富集病原体的方法
WO2014145958A2 (en) * 2013-03-15 2014-09-18 Seres Health, Inc. Network-based microbial compositions and methods
JP2016520305A (ja) 2013-05-03 2016-07-14 ネステク ソシエテ アノニム 消化管微生物叢中のラクノスピラ科細菌及び体重との関連性
WO2015018307A1 (en) 2013-08-06 2015-02-12 Bgi Shenzhen Co., Limited Biomarkers for colorectal cancer
EP3074027B1 (en) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
WO2015179437A1 (en) 2014-05-19 2015-11-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing clostridium difficile infection
DK3223835T3 (en) 2014-11-25 2025-02-17 Memorial Sloan Kettering Cancer Center Intestinal microbiota and gvhd
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2017008026A1 (en) * 2015-07-08 2017-01-12 Seres Therapeutics, Inc. Methods of treating colitis
US10300043B2 (en) 2015-08-12 2019-05-28 Mayo Foundation For Medical Education And Research Method for treating a gastrointestinal disorder in a mammal using bacteroides thetaiotaomicron and compositions thereof
CA2997100A1 (en) 2015-09-04 2017-03-09 Memorial Sloan-Kettering Cancer Center Methods and compositions for detecting risk of cancer relapse
WO2017074257A1 (en) 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
EP4233884A3 (en) 2015-11-24 2023-10-04 Seres Therapeutics, Inc. Designed bacterial compositions
CA3006105A1 (en) 2015-11-25 2017-06-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing vancomycin-resistant enterococci infection or colonization
KR20180094950A (ko) 2015-12-14 2018-08-24 메타보겐 에이비 간내 담즙정체증 및 관련 간 질환들의 치료
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
WO2017160944A2 (en) 2016-03-15 2017-09-21 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
ES2987655T7 (en) 2016-04-19 2025-04-29 Genome Res Ltd Bacteriotherapy
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
PT3468573T (pt) 2016-06-14 2023-10-16 Vedanta Biosciences Inc Tratamento de uma infeção por clostridium difficile
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
BR112020002992A2 (pt) 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
CN111432825A (zh) 2017-10-03 2020-07-17 赛里斯治疗公司 色胺代谢的操纵
CA3080586A1 (en) 2017-10-30 2019-05-09 Seres Therapeutics, Inc. Compositions and methods for treating antibiotic resistance
JP2021511827A (ja) 2018-01-23 2021-05-13 ザ ジェネラル ホスピタル コーポレイション ミトコンドリア機能を向上させる組成物および方法
CA3095356A1 (en) 2018-03-28 2019-10-03 Seres Therapeutics, Inc. Microbiome compositions for treatment of cancer
WO2019191694A1 (en) 2018-03-29 2019-10-03 Seres Therapeutics, Inc. Compositions and methods for treating inflammatory bowel diseases
US20210196766A1 (en) 2018-05-24 2021-07-01 Seres Therapeutics, Inc. Designed bacterial compositions and uses thereof
US20220017853A1 (en) 2018-12-05 2022-01-20 Seres Therapeutics, Inc. Compositions for stabilizing bacteria and uses thereof
BR112022010411A2 (pt) 2019-11-27 2022-08-23 Seres Therapeutics Inc Composições bacterianas projetadas e usos das mesmas

Also Published As

Publication number Publication date
US12214002B2 (en) 2025-02-04
CA3080586A1 (en) 2019-05-09
RU2020117775A (ru) 2021-12-01
KR20200079292A (ko) 2020-07-02
US20250288625A1 (en) 2025-09-18
BR112020008552A2 (pt) 2020-12-29
WO2019089643A1 (en) 2019-05-09
CN111432826A (zh) 2020-07-17
EP3703720A1 (en) 2020-09-09
AU2018360561A1 (en) 2020-05-21
US20200353018A1 (en) 2020-11-12
MX2020004495A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
JP2021501185A (ja) 抗生物質耐性を処置するための組成物及び方法
Di Bella et al. Clostridioides difficile infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options
Wei et al. Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics
Rossi et al. Occurrence and species level diagnostics of Campylobacter spp., enteric Helicobacter spp. and Anaerobiospirillum spp. in healthy and diarrheic dogs and cats
Said et al. Emergence of multidrug resistance and extensive drug resistance among enterococcal clinical isolates in Egypt
Kitagawa et al. Low incidence of Staphylococcus argenteus bacteremia in Hiroshima, Japan
Fastrès et al. Analysis of the lung microbiota in dogs with Bordetella bronchiseptica infection and correlation with culture and quantitative polymerase chain reaction
Rangaraju et al. Occurrence, antimicrobial resistance and virulence properties of thermophilic Campylobacter coli originating from two different poultry settings
Li et al. Prevalence and characteristics of Campylobacter from the genital tract of primates and ruminants in Eastern China
Bujňáková et al. Distribution of virulence-associated genes, antibiotic resistance and phylogenetic groups in Escherichia coli isolated from domestic and racing pigeons
Chibwe et al. A review of antibiotic resistance among Campylobacter species in human, animal, and water sources in South Africa: a One Health Approach
Dalwadi et al. Whole-genome sequencing of bacteria accountable for lactational mastitis in humans combined with an examination of their antibiotic resistance profiles
Carramaschi et al. First Identification of bla NDM-1 Producing Escherichia coli ST 9499 Isolated from Musca domestica in the Urban Center of Rio de Janeiro, Brazil
KR101384745B1 (ko) 병원성 유전자를 포함한 항생제 내성 Ｅ. ｃｏｌｉ 균주
Mai et al. Fecal carriage and molecular epidemiology of mcr-1-harboring Escherichia coli from children in southern China
El-Naenaeey et al. Foodborne Campylobacter species: Taxonomy, isolation, virulence attributes and antimicrobial resistance
Elkenany et al. Epidemiology of potential source, risk attribution of Clostridium perfringens from Egyptian broiler farms and genetic diversity of multidrug resistance strains
Mohamed Suffian et al. Antibiotic Resistant Escherichia coli Isolated from Faecal Samples of Cow at Livestock Farm in Kedah, Malaysia.
Kitcher Genomic epidemiology of multilocus sequence type 5 methicillin-resistant Staphylococcus aureus causing bacteraemia in Australia
Obanda Molecular Epidemiology of Staphylococcus Aureus From Hospital Patients, Hiv Positive and Negative Abattoir Workers and Animals in Busia County, Kenya
Ahmed et al. Phenotypic and genotypic characterisation of Salmonella serovars from poultry in ilorin, Kwara state, Nigeria
O'Grady Genomic epidemiology of human Clostridioides (Clostridium) difficile infection in Australia, 2013-2018
Johnson Illuminating the black box: aspects of Elizabethkingia epidemiology and antimicrobial resistance
Hassan et al. Research Article Distribution, Prevalence, and Antibiotic Susceptibility Profiles of Infectious Noncholera Vibrio Species in Malaysia
Metzger The Milk Microbiota of Healthy and Inflamed Bovine Mammary Glands

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231004

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240220